<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01105286</url>
  </required_header>
  <id_info>
    <org_study_id>PLQ-005</org_study_id>
    <secondary_id>2009-017393-20</secondary_id>
    <nct_id>NCT01105286</nct_id>
  </id_info>
  <brief_title>A Psoriasis Plaque Test Comparing Eight Different Formulations of Vitamin D Analogues for the Treatment of Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare the anti-psoriatic effect of eight different&#xD;
      formulations of vitamin D analogues using a psoriasis plaque test design&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Clinical Score of clinical symptoms</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical scores, lesions thickness</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <arm_group>
    <arm_group_label>Calcipotriol ointment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues</intervention_name>
    <description>Once daily application</description>
    <arm_group_label>Calcipotriol ointment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects having understood and signed an informed consent form.&#xD;
&#xD;
          -  Either sex&#xD;
&#xD;
          -  Age 18 years or above&#xD;
&#xD;
          -  All skin types and any ethnic origin&#xD;
&#xD;
          -  Subjects with a diagnosis of psoriasis vulgaris with lesions located on arms, legs or&#xD;
             trunk.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females who are pregnant, or who wish to become pregnant during the study, or who are&#xD;
             breast feeding&#xD;
&#xD;
          -  Systemic treatment with biological therapies (marketed or not marketed) with a&#xD;
             possible effect on psoriasis vulgaris within 4 weeks (etanercept), 2 months&#xD;
             (adalimumab, alefacept, infliximab), 4 months (ustekinumab) or 4 weeks/5 half-lives&#xD;
             (which-ever is longer) for experimental biological products prior to randomisation&#xD;
&#xD;
          -  Systemic treatments with all other therapies than biologicals, with a potential effect&#xD;
             on psoriasis vulgaris (e.g., corticosteroids, vitamin D analogues, retinoids,&#xD;
             immuno-suppressants) within the 4-week period prior to randomisation&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis&#xD;
             within the 4 week period prior to randomisation and during the study:&#xD;
&#xD;
               -  Potent or very potent (WHO group III-IV) corticosteroids&#xD;
&#xD;
               -  PUVA or Grenz ray therapy&#xD;
&#xD;
          -  Subjects using one of the following topical drugs for the treatment of psoriasis&#xD;
             within two weeks prior to randomisation and during the study:&#xD;
&#xD;
               -  WHO group I-II corticosteroids (except if used for treatment of scalp psoriasis)&#xD;
&#xD;
               -  Topical retinoids&#xD;
&#xD;
               -  Vitamin D analogues&#xD;
&#xD;
               -  Topical immunomodulators (e.g. macrolides)&#xD;
&#xD;
               -  Anthracen derivatives&#xD;
&#xD;
               -  Tar&#xD;
&#xD;
               -  Salicylic acid&#xD;
&#xD;
               -  UVB therapy&#xD;
&#xD;
          -  Subjects known to be non-responder to topical vitamin D analogues (e.g., known history&#xD;
             of no improvement or worsening of psoriasis with e.g., calcipotriol, calcitriol or&#xD;
             tacalcitol when used according to current SmPc)&#xD;
&#xD;
          -  Subjects who have received treatment with any non-marketed drug substance (i.e., an&#xD;
             agent which has not yet been made available for clinical use following registration)&#xD;
             within the 4 week period prior to randomisation or longer, if the class of the&#xD;
             substance requires a longer washout as defined above (e.g., biological treatments)&#xD;
&#xD;
          -  Subjects with current participation in any other interventional clinical, based on&#xD;
             interview of the subject&#xD;
&#xD;
          -  Subjects with current diagnosis of guttate, erythrodermic, exfoliative or pustular&#xD;
             psoriasis&#xD;
&#xD;
          -  Subjects with known or suspected hypersensitivity to component(s) of the&#xD;
             investigational products&#xD;
&#xD;
          -  Subjects with known/suspected disorders of calcium metabolism associated with&#xD;
             hypercalcaemia&#xD;
&#xD;
          -  Subjects with known severe hepatic and/or severe renal insufficiency&#xD;
&#xD;
          -  Subjects with any concomitant medical or dermatological disorder(s) which might&#xD;
             preclude accurate evaluation of the psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice Facy, PhD</last_name>
    <role>Study Director</role>
    <affiliation>LEO Pharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>LEO Pharma site</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>April 15, 2010</study_first_submitted>
  <study_first_submitted_qc>April 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2010</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Calcipotriene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

